Get the latest news, insights, and market updates on BAX (Baxter International Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
How Recent Moves Are Rewriting The Story For Baxter International (BAX)
Baxter International’s latest price target work keeps the fair value estimate clustered around US$23.13 per share, with only a small adjustment to the discount rate and revenue growth assumptions. This signals that recent information has not materially reshaped the core story in the models behind that number. Street research is still split between the low US$20s and US$30 range, but there is clear focus on how upcoming Q4 results and the 2026 outlook might either confirm or challenge the... Feb 4, 2026 - $BAX
Reassessing Baxter International (BAX) Valuation After A Mixed Return Profile And 2026 Outlook Focus
What recent performance data suggests for Baxter International (BAX) Baxter International (BAX) has been on many investors’ radars after a mixed stretch, with a 1-month return of 2.1%, a 3-month return of 10.9%, and a 1-year total return decline of 35.5%. At a last close of US$19.91, the company carries a value score of 4, supported by reported annual revenue of US$11.0b and a net income loss of US$344.0m. This combination helps frame the risk and reward trade-off that investors are currently... Feb 4, 2026 - $BAX
How Investors May Respond To Baxter (BAX) Earnings Miss, Dividend Cut And Novum IQ Setback
Baxter International recently reported third-quarter 2025 results with adjusted earnings per share ahead of expectations but revenue of US$2.84 billion below forecasts, alongside a dividend cut, hurricane-related production disruptions, and continued shipment holds on its Novum IQ infusion pumps following safety concerns. At the same time, Baxter advanced its position in the growing advanced wound closure market by launching a next-generation Artiss fibrin sealant spray for large-area burn... Feb 4, 2026 - $BAX
Here’s What Hit Baxter (BAX) in Q4
Pzena Investment Management recently released its fourth-quarter 2025 commentary for “Pzena Focused Value Strategy.” A copy of the letter can be downloaded here. The fourth quarter was defined by strong AI momentum and continued market dominance by mega-cap stocks. In this environment, Pzena Focused Value Strategy underperformed the Russell 1000® Value Index, delivering a net return of […] Feb 3, 2026 - $BAX
4 Medical Product Stocks to Watch From a Challenging Industry
The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals. Feb 2, 2026 - $BAX
Does Baxter International (BAX) Offer Opportunity After Prolonged Share Price Weakness?
If you are wondering whether Baxter International's share price still reflects its underlying business, the key question is whether the stock now offers value or just looks cheap on the surface. The stock recently closed at US$20.07, with returns of 1.2% over 7 days and 2.9% over 30 days. However, over the longer term it shows a 37.2% decline over 1 year, 53.6% over 3 years and 71.1% over 5 years, which raises very different questions about risk and opportunity. Recent coverage around Baxter... Feb 1, 2026 - $BAX
Baxter Disruptions Test Recovery Prospects And Perceived Value Opportunity
Baxter International (NYSE:BAX) is dealing with operational disruptions at its North Cove facility following hurricane related impacts. The company has also placed a shipment hold on its Novum IQ infusion pump after safety concerns and two reported patient deaths. These issues affect both production capacity and a key medical device product line, raising fresh operational and reputational questions. Baxter International enters this period of disruption with its shares at $20.07 and a 1 year... Jan 31, 2026 - $BAX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple